Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 60/100

2nd Australian site for Nanomab-PDL-1 Phase 1 trial

Wednesday, December 27, 2023 1 min read
Key Takeaway: Radiopharm Theranostics has announced the initiation of a second Australian site for its Nanomab-PDL-1 Phase 1 trial. This expansion signifies a step forward in the clinical development of the therapy, aimed at enhancing treatment options. The trial's progression is a positive indicator of the company's commitment to advancing its research efforts.

Market Sentiment Analysis

POSITIVE FACTORS

  • Second site for the trial indicates progress in research.
  • Phase 1 trial reflects ongoing commitment to clinical development.

Full Press Release Details

• Announcements
• Price Sensitive
• December 27, 2023
Loading Viewer…

More Announcements & Updates

• Announcements
• June 14, 2022
• Announcements
• September 28, 2023
• Announcements
• May 30, 2025
• Announcements
• May 30, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the Nanomab-PDL-1 trial about?

The Nanomab-PDL-1 trial is a Phase 1 clinical study aimed at evaluating a new therapeutic approach.

Why is a second site being opened in Australia?

The second site in Australia is part of the effort to enhance the trial's reach and patient enrollment.

Who is conducting the Nanomab-PDL-1 trial?

The trial is being conducted by Radiopharm Theranostics, a company focused on innovative therapies.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics Nanomab-PDL-1 Phase 1 trial clinical development Australia
Last updated: Dec 27, 2023